ºñ±¸¾Æ´Ïµå(Biguanides) ½ÃÀå, Á¡À¯À², ±Ô¸ð, µ¿Çâ, »ê¾÷ ºÐ¼® º¸°í¼­ : À¯Çüº°, À¯Åë ä³Îº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2032³â)

The global Biguanides market size is expected to reach USD 6.19 billion by 2032, according to a new study by Polaris Market Research. The report "Biguanides Market Share, Size, Trends, Industry Analysis Report, By Type (Metformin, Phenformin, Others); By Distribution Channel; By Region; Segment Forecast, 2024- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Ongoing efforts focus on innovating formulations, exploring combination therapies, and expanding the applications of biguanides in diabetes care. The commitment to enhancing clinical efficacy, safety, and patient outcomes is evident in the exploration of novel drug delivery systems and formulations. Research also investigates potential cardiometabolic benefits beyond glycemic control, broadening the therapeutic scope of biguanides. Collaborations between pharmaceutical entities and academic institutions drive innovation, ensuring that ongoing research contributes to the sustained significance of biguanides in the dynamic landscape of antidiabetic therapies.

Telehealth integration is a driving force behind the growth of the biguanides market. As diabetes management evolves towards personalized care, telehealth platforms streamline remote patient monitoring for better outcomes. Real-time tracking of blood glucose levels and medication adherence enhances the efficacy of biguanides, particularly in diabetes treatment. Virtual consultations enable prompt adjustments to medication regimens, fostering patient engagement. This integration not only improves patient care but also contributes valuable data for ongoing research in diabetes management. The convenience offered by telehealth enhances patient compliance, fueling the demand for biguanides and propelling market expansion.

Patient-centric formulations are driving the expansion of the biguanides market. Aligned with the trend towards personalized healthcare, these tailored formulations, including extended-release options, boost the appeal and efficacy of biguanides. They enhance medication adherence by minimizing side effects and simplifying dosing regimens, prioritizing patient comfort and compliance. Improved satisfaction and adherence not only optimize treatment outcomes but also heighten the market desirability of biguanides.

Combination therapies are propelling biguanides market growth by exploring synergies between biguanides and other therapeutic classes. This research and development avenue offers novel opportunities for heightened treatment efficacy. By combining biguanides with complementary drugs like insulin sensitizers, there's potential for improved glycemic control and minimized side effects. This strategy not only tackles the multifaceted nature of diabetes but also diversifies treatment options for patients. Pharmaceutical companies investing in pioneering combination therapies strategically position themselves to leverage the evolving diabetes management landscape, advancing the biguanides market with comprehensive and tailored solutions.

Biguanides Market Report Highlights

In 2023, the metformin segment accounted for significant market share owing to efficacy, safety profile, and affordability.

In 2023, the retail pharmacy segment held significant revenue share owing to convenient access for patients and widespread availability.

In 2023, North America region dominated the global market due to rising diabetes cases, and an aging population.

The market is highly competitive owing to the existence of market players with a global presence, including AstraZeneca, Bayer AG, Boehringer Ingelheim, Dr. Reddy's Laboratories, Eli Lilly and Company, GlaxoSmithKline, Pfizer Inc., and Sanofi among others.

Polaris Market Research has segmented the Biguanides market report based on type, distribution channel, and region:

Biguanides, Type Outlook (Revenue - USD Billion, 2019 - 2032)

• Metformin
• Phenformin
• Others

Biguanides, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

• Retail Pharmacy
• Hospital Pharmacy
• Others

Biguanides, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

• North America
• U.S.
• Canada
• Europe
• France
• Germany
• UK
• Italy
• Netherlands
• Spain
• Russia
• Asia Pacific
• Japan
• China
• India
• Malaysia
• Indonesia
• South Korea
• Latin America
• Brazil
• Mexico
• Argentina
• Middle East & Africa
• Saudi Arabia
• UAE
• Israel
• South Africa

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Biguanides Market Insights

• 4.1. Biguanides Market - Industry Snapshot
• 4.2. Biguanides Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. First-Line Treatment is projected to spur the product demand
    • 4.2.1.2. Surging prevalence of type 2 diabetes is expected to drive market growth
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. Prevalence of side effects is likely to impede the market growth
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTLE Analysis
• 4.5. Biguanides Industry trends
• 4.6. Value Chain Analysis
• 4.7. COVID-19 Impact Analysis

5. Global Biguanides Market, by Type

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Biguanides, by Type, 2019-2032 (USD Billion)
• 5.3. Metformin
  • 5.3.1. Global Biguanides Market, by Metformin, by Region, 2019-2032 (USD Billion)
• 5.4. Phenformin
  • 5.4.1. Global Biguanides Market, by Phenformin, by Region, 2019-2032 (USD Billion)
• 5.5. Others
  • 5.5.1. Global Biguanides Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Biguanides Market, by Distribution Channel

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
• 6.3. Retail Pharmacy
  • 6.3.1. Global Biguanides Market, by Retail Pharmacy, by Region, 2019-2032 (USD Billion)
• 6.4. Hospital Pharmacy
  • 6.4.1. Global Biguanides Market, by Hospital Pharmacy, by Region, 2019-2032 (USD Billion)
• 6.5. Others
  • 6.5.1. Global Biguanides Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Biguanides Market, by Geography

• 7.1. Key findings
• 7.2. Introduction
  • 7.2.1. Biguanides Market Assessment, By Geography, 2019-2032 (USD Billion)
• 7.3. Biguanides Market - North America
  • 7.3.1. North America: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 7.3.2. North America: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • 7.3.3. Biguanides Market - U.S.
    • 7.3.3.1. U.S.: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 7.3.3.2. U.S.: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • 7.3.4. Biguanides Market - Canada
    • 7.3.4.1. Canada: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 7.3.4.2. Canada: Biguanides Market, by Type, 2019-2032 (USD Billion)
• 7.4. Biguanides Market - Europe
  • 7.4.1. Europe: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 7.4.2. Europe: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • 7.4.3. Biguanides Market - UK
    • 7.4.3.1. UK: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 7.4.3.2. UK: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • 7.4.4. Biguanides Market - France
    • 7.4.4.1. France: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 7.4.4.2. France: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • 7.4.5. Biguanides Market - Germany
    • 7.4.5.1. Germany: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 7.4.5.2. Germany: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • 7.4.6. Biguanides Market - Italy
    • 7.4.6.1. Italy: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 7.4.6.2. Italy: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • 7.4.7. Biguanides Market - Spain
    • 7.4.7.1. Spain: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 7.4.7.2. Spain: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • 7.4.8. Biguanides Market - Netherlands
    • 7.4.8.1. Netherlands: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 7.4.8.2. Netherlands: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • 7.4.9. Biguanides Market - Russia
    • 7.4.9.1. Russia: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 7.4.9.2. Russia: Biguanides Market, by Type, 2019-2032 (USD Billion)
• 7.5. Biguanides Market - Asia Pacific
  • 7.5.1. Asia Pacific: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 7.5.2. Asia Pacific: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • 7.5.3. Biguanides Market - China
    • 7.5.3.1. China: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 7.5.3.2. China: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • 7.5.4. Biguanides Market - India
    • 7.5.4.1. India: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 7.5.4.2. India: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • 7.5.5. Biguanides Market - Malaysia
    • 7.5.5.1. Malaysia: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 7.5.5.2. Malaysia: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • 7.5.6. Biguanides Market - Japan
    • 7.5.6.1. Japan: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 7.5.6.2. Japan: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • 7.5.7. Biguanides Market - Indonesia
    • 7.5.7.1. Indonesia: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 7.5.7.2. Indonesia: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • 7.5.8. Biguanides Market - South Korea
    • 7.5.8.1. South Korea: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 7.5.8.2. South Korea: Biguanides Market, by Type, 2019-2032 (USD Billion)
• 7.6. Biguanides Market - Middle East & Africa
  • 7.6.1. Middle East & Africa: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 7.6.2. Middle East & Africa: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • 7.6.3. Biguanides Market - Saudi Arabia
    • 7.6.3.1. Saudi Arabia: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 7.6.3.2. Saudi Arabia: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • 7.6.4. Biguanides Market - UAE
    • 7.6.4.1. UAE: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 7.6.4.2. UAE: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • 7.6.5. Biguanides Market - Israel
    • 7.6.5.1. Israel: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 7.6.5.2. Israel: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • 7.6.6. Biguanides Market - South Africa
    • 7.6.6.1. South Africa: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 7.6.6.2. South Africa: Biguanides Market, by Type, 2019-2032 (USD Billion)
• 7.7. Biguanides Market - Latin America
  • 7.7.1. Latin America: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 7.7.2. Latin America: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • 7.7.3. Biguanides Market - Mexico
    • 7.7.3.1. Mexico: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 7.7.3.2. Mexico: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • 7.7.4. Biguanides Market - Brazil
    • 7.7.4.1. Brazil: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 7.7.4.2. Brazil: Biguanides Market, by Type, 2019-2032 (USD Billion)
  • 7.7.5. Biguanides Market - Argentina
    • 7.7.5.1. Argentina: Biguanides Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 7.7.5.2. Argentina: Biguanides Market, by Type, 2019-2032 (USD Billion)

8. Competitive Landscape

• 8.1. Expansion and Acquisition Analysis
  • 8.1.1. Expansion
  • 8.1.2. Acquisitions
• 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

• 9.1. AstraZeneca
  • 9.1.1. Company Overview
  • 9.1.2. Financial Performance
  • 9.1.3. Product Benchmarking
  • 9.1.4. Recent Development
• 9.2. Bayer AG
  • 9.2.1. Company Overview
  • 9.2.2. Financial Performance
  • 9.2.3. Product Benchmarking
  • 9.2.4. Recent Development
• 9.3. Boehringer Ingelheim
  • 9.3.1. Company Overview
  • 9.3.2. Financial Performance
  • 9.3.3. Product Benchmarking
  • 9.3.4. Recent Development
• 9.4. Bristol Myers Squibb
  • 9.4.1. Company Overview
  • 9.4.2. Financial Performance
  • 9.4.3. Product Benchmarking
  • 9.4.4. Recent Development
• 9.5. Dr. Reddy's Laboratories
  • 9.5.1. Company Overview
  • 9.5.2. Financial Performance
  • 9.5.3. Product Benchmarking
  • 9.5.4. Recent Development
• 9.6. Eli Lilly and Company
  • 9.6.1. Company Overview
  • 9.6.2. Financial Performance
  • 9.6.3. Product Benchmarking
  • 9.6.4. Recent Development
• 9.7. GlaxoSmithKline
  • 9.7.1. Company Overview
  • 9.7.2. Financial Performance
  • 9.7.3. Product Benchmarking
  • 9.7.4. Recent Development
• 9.8. Lupin Pharmaceuticals, Inc.
  • 9.8.1. Company Overview
  • 9.8.2. Financial Performance
  • 9.8.3. Product Benchmarking
  • 9.8.4. Recent Development
• 9.9. Merck & Co., Inc.
  • 9.9.1. Company Overview
  • 9.9.2. Financial Performance
  • 9.9.3. Product Benchmarking
  • 9.9.4. Recent Development
• 9.10. Novartis
  • 9.10.1. Company Overview
  • 9.10.2. Financial Performance
  • 9.10.3. Product Benchmarking
  • 9.10.4. Recent Development
• 9.11. Pfizer Inc.
  • 9.11.1. Company Overview
  • 9.11.2. Financial Performance
  • 9.11.3. Product Benchmarking
  • 9.11.4. Recent Development
• 9.12. Sanofi
  • 9.12.1. Company Overview
  • 9.12.2. Financial Performance
  • 9.12.3. Product Benchmarking
  • 9.12.4. Recent Development
• 9.13. Sun Pharmaceutical Industries Ltd.
  • 9.13.1. Company Overview
  • 9.13.2. Financial Performance
  • 9.13.3. Product Benchmarking
  • 9.13.4. Recent Development
• 9.14. Teva Pharmaceutical Industries Ltd.
  • 9.14.1. Company Overview
  • 9.14.2. Financial Performance
  • 9.14.3. Product Benchmarking
  • 9.14.4. Recent Development
• 9.15. Zydus Cadila
  • 9.15.1. Company Overview
  • 9.15.2. Financial Performance
  • 9.15.3. Product Benchmarking
  • 9.15.4. Recent Development